Ocular Surface Disease Changes After iStent or iStent Inject Implantation With Phacoemulsification

This study enrolled eyes with mild to moderate open-angle glaucoma (OAG) on 1-4 glaucoma medications who were scheduled to undergo phacoemulsification cataract extraction and trabecular micro-bypass stent(s) implantation (iStent or iStent inject). Study participation entailed measurement of key ocular surface data through 3 months postoperative including Ocular Surface Disease Index score (OSDI), corneal/conjunctival staining (Oxford Schema), fluorescein tear break-up time (FTBUT), and conjunctival hyperemia (Efron Scale); these measures were collected alongside standard postoperative glaucoma evaluations such as number of glaucoma medications and intraocular pressure (IOP).

Inclusion criteria

• Mild to moderate primary open-angle glaucoma
• Currently treated with ocular hypotensive medication
• Primary open-angle, pseudoexfoliative and pigmentary glaucoma are acceptable diagnoses
• Subject scheduled to undergo cataract surgery in combination with one trabecular meshwork bypass stent
• 22 years of age or older
• Able and willing to attend scheduled follow-up exams for three months postoperatively
• Able and willing to provide written informed consent on the IRB approved Informed Consent Form
• Successful, uncomplicated cataract surgery
• OSDI of 8 or more

Exclusion criteria

• 1. Primary angle-closure glaucoma; or secondary angle closure glaucoma, including neovascular glaucoma 2. Any pathology for which, in the investigator's judgement, the following would be either at risk or contraindicated:

• Cataract surgery
• Stent implantation
• Compliance to elements of the study protocol (e.g., ophthalmic examinations, follow-up visits) 3. Fellow eye actively enrolled in this trial 4. Current participation in any study, or participation within 30 calendar days of screening exam 5. Unsuccessful, complicated cataract surgery 6. OSDI of 7 or less